ReviewJournal of fungi (Basel, Switzerland)2026
Active Screening for
Review in Journal of fungi (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundPatients' and surfaces' colonisation play a pivotal role in
methodsThis systematic review searched studies regarding
resultsThirty-eight studies published between 2019 and 2023 across 18 countries were included using well-established inclusion criteria. Various body sites were screened mainly in patients admitted to intensive care units (ICUs). Patients had various comorbidities and were more commonly colonised during hospitalisation, compared to admission. Most of the isolates belonged to Clade I. Of 19 studies determining antifungal susceptibility, 15 reported resistance, mainly to azoles. Azole resistance was consistently associated with
conclusionsHealthcare workers should be on high alert for older, long-term hospitalised, ICU patients with comorbidities and co-colonisation with other pathogens. Composite bilateral axilla-groin sampling should remain the standard minimum approach. Additional anatomical sites may be considered. Well-equipped laboratories are vital for precision identification and antifungal susceptibility testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.